TY - JOUR
T1 - Use of fluorescent substrates for characterization of Gaucher disease mutations
AU - Ron, Idit
AU - Dagan, Arie
AU - Gatt, Shimon
AU - Pasmanik-Chor, Metzada
AU - Horowitz, Mia
N1 - Funding Information:
This work was supported by a grant from Genzyme Corp. USA to M.H. and the Israel Science Foundation (Grant no. 648/02, to M.H and Grant no 607/02 to S.G. and A.D).
PY - 2005/7
Y1 - 2005/7
N2 - Gaucher disease results from impaired activity of the lysosomal enzyme β-glucocerebrosidase. More than 200 mutations within the glucocerebrosidase gene have been associated with this disease. In this study we tested the effect of several mutations (K157Q, D140H, E326K, D140H+E326K, V394L and R463C) on RNA stability, protein stability and activity toward four different fluorescent substrates (LR-12-GC, Bodipy-12-GC, LR-0-PAP-glucose and 4-MUG), using the vaccinia-derived expression system. The results indicated that the K157Q mutation leads to RNA instability, causing low protein levels and a concomitant reduction in β-glucocerebrosidase activity. All other tested mutations led to production of glucocerebrosidase RNA and protein with stabilities comparable to those of the normal counterpart. The D140H variant exhibited a high activity toward the tested substrates while the variant enzymes containing either the E326K or D140H and E326k mutations together expressed low β- glucocerebrosidase activity. The V394L variant exhibited low activity toward the tested substrates, while a higher activity was presented by the R463C containing glucocerebrosidase variant. Our results strongly indicated that the LR-12-GC substrate distinguishes between severities of different mutant glucocerebrosidase variants overexpressed in a heterologous system.
AB - Gaucher disease results from impaired activity of the lysosomal enzyme β-glucocerebrosidase. More than 200 mutations within the glucocerebrosidase gene have been associated with this disease. In this study we tested the effect of several mutations (K157Q, D140H, E326K, D140H+E326K, V394L and R463C) on RNA stability, protein stability and activity toward four different fluorescent substrates (LR-12-GC, Bodipy-12-GC, LR-0-PAP-glucose and 4-MUG), using the vaccinia-derived expression system. The results indicated that the K157Q mutation leads to RNA instability, causing low protein levels and a concomitant reduction in β-glucocerebrosidase activity. All other tested mutations led to production of glucocerebrosidase RNA and protein with stabilities comparable to those of the normal counterpart. The D140H variant exhibited a high activity toward the tested substrates while the variant enzymes containing either the E326K or D140H and E326k mutations together expressed low β- glucocerebrosidase activity. The V394L variant exhibited low activity toward the tested substrates, while a higher activity was presented by the R463C containing glucocerebrosidase variant. Our results strongly indicated that the LR-12-GC substrate distinguishes between severities of different mutant glucocerebrosidase variants overexpressed in a heterologous system.
KW - Fluorescent substrate
KW - Gaucher disease
KW - β-glucocerebrosidase
UR - http://www.scopus.com/inward/record.url?scp=21544481475&partnerID=8YFLogxK
U2 - 10.1016/j.bcmd.2005.03.006
DO - 10.1016/j.bcmd.2005.03.006
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:21544481475
SN - 1079-9796
VL - 35
SP - 57
EP - 65
JO - Blood Cells, Molecules, and Diseases
JF - Blood Cells, Molecules, and Diseases
IS - 1
ER -